Form 4: SOPHIA GENETICS: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that President Ross Muken sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• President Ross Muken of SOPHiA GENETICS SA sold a total of 5,024 ordinary shares across two transactions on April 6th and April 7th, 2026.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2nd and 3rd, 2026.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating they were not discretionary trades.
• On April 6th, 2,600 shares were sold at a weighted average price of $4.8474, with individual sale prices ranging from $4.6150 to $4.95.
• On April 7th, 2,424 shares were sold at a weighted average price of $4.8686, with individual sale prices ranging from $4.77 to $4.98.
• Following these transactions, Ross Muken beneficially owns 698,097 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves insider selling, the clear explanation of tax withholding and the use of a Rule 10b5-1 plan mitigate significant negative sentiment.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which is designed to comply with insider trading regulations and demonstrates pre-planned financial management.
• The sales were specifically to cover tax withholding obligations, a common and expected event for executives receiving equity compensation.

Negatives

• An insider, the President, has sold a portion of their holdings, which could be perceived negatively by the market, despite the stated reason.
• The total number of shares sold (5,024) represents a small fraction of the President's total beneficial ownership (698,097 shares).

Risks

• Potential for negative market perception of insider selling, even when conducted under a pre-planned trading strategy for tax purposes.
• The weighted average pricing indicates a range of sales prices, suggesting market volatility during the transaction period.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by SOPHiA GENETICS' President is a common practice to manage equity sales in a compliant manner, particularly for covering tax liabilities, and is generally viewed neutrally by the market when executed as described.

Stakeholder Impact

• Shareholders: May observe the insider selling, but the explanation of tax withholding and the Rule 10b5-1 plan should temper concerns about a lack of confidence from management.
• Employees: The transaction highlights the equity-based compensation structure and its tax implications for executives.
• Management: Demonstrates adherence to regulatory requirements for reporting ownership changes and managing personal finances related to compensation.

Next Steps

• The reporting person will continue to hold the remaining 698,097 ordinary shares.
• The company may continue to have executives utilize Rule 10b5-1 plans for future equity compensation events.

Key Dates

Keywords

SOPHIA GENETICS, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, Beneficial Ownership